Literature DB >> 11807985

Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2.

Peter H Wessels1, Albert Twijnstra, Alfons G H Kessels, Bela Krijne-Kubat, Paul H Theunissen, Monique I J Ummelen, Frans C S Ramaekers, Anton H Hopman.   

Abstract

The clinical course of astrocytoma grade 2 (A2) is highly variable and is not reflected by morphological characteristics. Earlier studies using small series of A2 cases suggest that in situ hybridization (ISH) with chromosome-specific DNA probes allows for frequent detection of aneusomy 1, trisomy 7, and monosomy 10. The role of trisomy 7 in astrocytoma carcinogenesis is disputed, however, because of its presence in non-neoplastic brain tissue, as detected by karyotyping. Our objective was to investigate whether there was a correlation between chromosomal aberrations and survival in a series of 47 cases of A2. All cases were evaluated for numerical aberrations of chromosomes 1, 7, and 10 by ISH. Chromosomal aberrations were detected in 68% of cases of A2. Trisomy/polysomy 7 was seen in 31 cases (66%), 22 of which (47%) had a high percentage of this numerical aberration. Only 11 of these 22 cases also showed aneusomy for 1 or 10. No cells or only a few cells with aberrations were detected in non-neoplastic control samples. Using Kaplan-Meier analysis, trisomy/polysomy 7 correlated significantly with shorter survival. Hence, as determined by ISH, trisomy/polysomy 7 is absent in non-neoplastic brain tissue and is frequently detected in A2, correlating with the malignant progression of the disease. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11807985     DOI: 10.1002/gcc.10029

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  15 in total

1.  Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization.

Authors:  Mariarita Santi; Martha Quezado; Rubin Ronchetti; Elisabeth J Rushing
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

2.  Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.

Authors:  Silke Wemmert; Ralf Ketter; Jörg Rahnenführer; Niko Beerenwinkel; Martin Strowitzki; Wolfgang Feiden; Christian Hartmann; Thomas Lengauer; Florian Stockhammer; Klaus D Zang; Eckart Meese; Wolf-Ingo Steudel; Andreas von Deimling; Steffi Urbschat
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

3.  Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification.

Authors:  Barbara Klink; Ben Schlingelhof; Martin Klink; Karen Stout-Weider; Stephan Patt; Evelin Schrock
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

4.  High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas.

Authors:  Kasumi Araki; Kazuhiko Nozaki; Tetsuya Ueba; Masaaki Tatsuka; Nobuo Hashimoto
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 5.  Pathology and molecular genetics of astrocytic gliomas.

Authors:  Guido Reifenberger; Vincent Peter Collins
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

6.  Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Authors:  Rodney N Wiltshire; James E Herndon; Annie Lloyd; Henry S Friedman; Darell D Bigner; Sandra H Bigner; Roger E McLendon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

7.  Whole Chromosome 7 Gain Predicts Higher Risk of Recurrence in Pediatric Pilocytic Astrocytomas Independently From KIAA1549-BRAF Fusion Status.

Authors:  Jacquelyn J Roth; Tamara M Fierst; Angela J Waanders; Li Yimei; Jaclyn A Biegel; Mariarita Santi
Journal:  J Neuropathol Exp Neurol       Date:  2016-03-04       Impact factor: 3.685

Review 8.  The role of neuropathology in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Daniel J Brat; Timothy Charles Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-15       Impact factor: 4.130

9.  BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

Authors:  Stefan Pfister; Wibke G Janzarik; Marc Remke; Aurélie Ernst; Wiebke Werft; Natalia Becker; Grischa Toedt; Andrea Wittmann; Christian Kratz; Heike Olbrich; Rezvan Ahmadi; Barbara Thieme; Stefan Joos; Bernhard Radlwimmer; Andreas Kulozik; Torsten Pietsch; Christel Herold-Mende; Astrid Gnekow; Guido Reifenberger; Andrey Korshunov; Wolfram Scheurlen; Heymut Omran; Peter Lichter
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

10.  A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.

Authors:  Sandra Camelo-Piragua; Michael Jansen; Aniruddha Ganguly; James ChulMin Kim; Arjola K Cosper; Dora Dias-Santagata; Catherine L Nutt; A John Iafrate; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2011-02       Impact factor: 3.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.